NCT02156375View on ClinicalTrials.gov

A Pharmacokinetic Study of Single-Dose Intravenous Ustekinumab Delivered in 2 Different Liquid in Vial Formulations

PHASE1CompletedINTERVENTIONAL

Enrollment

140

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions

Healthy

Interventions

DRUG

Ustekinumab

Participants will receive a single 6 milligram per kilogram (mg/kg) intravenous infusion of 90 milligram per milliliter (mg/mL) liquid in vial (LIV) formulation, diluted in saline, on Day 1.

DRUG

Ustekinumab

Participants will receive a single 6 mg/kg intravenous infusion of 5 mg/mL LIV formulation, diluted in saline, on Day 1.

Trial Locations (3)

Unknown

Tempe

Lincoln

Neptune City

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT02156375 - A Pharmacokinetic Study of Single-Dose Intravenous Ustekinumab Delivered in 2 Different Liquid in Vial Formulations | Biotech Hunter | Biotech Hunter